Reply to Cardenas et al. [2]

Journal of Infectious Diseases

Volumn 194, Issue 5, 2006, Pages 714-716

  Gessner, Bradford D ^a,d   Baggett, Henry C ^a   Dunaway, Eitel ^b   Gold, Benjamin D ^c   Parkinson, Alan J ^b  

^a Alaska Division of Public Health   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; FERRITIN; IRON; METRONIDAZOLE;

ANEMIA; DRUG EFFICACY; ERADICATION THERAPY; FERRITIN BLOOD LEVEL; FOLLOW UP; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IRON DEFICIENCY; IRON STORAGE; LETTER; PRIORITY JOURNAL; RISK FACTOR; TREATMENT FAILURE; UNITED STATES;

EID: 33748091363     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/505717     Document Type: Letter

References (3)

1. Gessner BD, Baggett HC, Muth PT, et al. A controlled, household-randomized controlled open-label trial of the effect that treatment of Helicobacter pylori infection has on iron deficiency among children in rural Alaska. J Infect Dis 2006; 193:537-46.
2. Gessner BD, Bruce MG, Parkinson AJ, et al. A randomized trial of triple therapy for pediatric Helicobacter pylori infection and risk factors for treatment failure in a population with a high prevalence of infection. Clin Infect Dis 2005; 41:1261-8.
3. Baggett HC, Parkinson AJ, Muth PT, et al. Endemic iron deficiency associated with Helicobacter pylori infection among school-aged children in Alaska. Pediatrics 2006; 117:e396-404.